Nurix Therapeutics, Inc. (NRIX)
| Market Cap | 2.82B +115.0% |
| Revenue (ttm) | 701.94M +738.8% |
| Net Income | 294.88M |
| EPS | 2.69 |
| Shares Out | 109.25M |
| PE Ratio | 9.60 |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 4,386,940 |
| Open | 25.72 |
| Previous Close | 25.70 |
| Day's Range | 25.63 - 26.55 |
| 52-Week Range | 11.67 - 28.23 |
| Beta | 1.78 |
| Analysts | Buy |
| Price Target | 33.86 (+31.14%) |
| Earnings Date | Oct 12, 2026 |
About NRIX
Nurix Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and antibody therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-5948, an orally bioavailable BTK degrader that is in Phase 2 clinical trials for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; NX-2127, an orally bioavailable Bruton’s tyrosine kinase (BTK) degrader, which is in Phase 1a/1b clinical trials f... [Read more]
Financial Performance
In fiscal year 2025, Nurix Therapeutics's revenue was $83.98 million, an increase of 53.95% compared to the previous year's $54.55 million. Losses were -$264.46 million, 36.6% more than in 2024.
Financial StatementsAnalyst Summary
According to 14 analysts, the average rating for NRIX stock is "Buy." The 12-month stock price target is $33.86, which is an increase of 31.14% from the latest price.
News
Nurix Therapeutics partner Sanofi discontinues STAT6 degrader SAR448272
Nurix Therapeutics (NRIX) announced that Sanofi notified Nurix of its decision to discontinue the Phase 1 first-in-human clinical trial of SAR448272, an oral STAT6 degrader, and to terminate the SAR44...
Nurix Therapeutics Announces Sanofi's Decision to Discontinue Development of STAT6 Degrader SAR448272
BRISBANE, Calif., Nov. 03, 2026 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on targeted protein degradation medicines, today announc...
Nurix Therapeutics management to meet with Piper Sandler
Investor Dinner Meeting with Management to be held in Boston on October 28 hosted by Piper Sandler.
Nurix Therapeutics price target raised to $36 from $34 at H.C. Wainwright
H.C. Wainwright raised the firm’s price target on Nurix Therapeutics (NRIX) to $36 from $34 and keeps a Buy rating on the shares. The firm reduced the company’s long-term operating…
Nurix Therapeutics price target lowered to $33 from $34 at Truist
Truist analyst Gregory Renza lowered the firm’s price target on Nurix Therapeutics (NRIX) to $33 from $34 and keeps a Buy rating on the shares after its Q3 results. The…
Nurix Therapeutics price target lowered to $35 from $36 at RBC Capital
RBC Capital analyst Brian Abrahams lowered the firm’s price target on Nurix Therapeutics (NRIX) to $35 from $36 and keeps an Outperform rating on the shares after the company’s Q3…
Nurix Therapeutics price target raised to $32 from $28 at Oppenheimer
Oppenheimer raised the firm’s price target on Nurix Therapeutics (NRIX)to $32 from $28 and keeps an Outperform rating on the shares. The firm notes the company finished Q3 with an…
Nurix Therapeutics price target raised to $36 from $33 at Baird
Baird raised the firm’s price target on Nurix Therapeutics (NRIX) to $36 from $33 and keeps an Outperform rating on the shares. The firm updated its model following Q3 results.
Nurix Therapeutics Earnings release: Q3 2026
Nurix Therapeutics released its Q3 2026 earnings on October 13, 2026, summarizing the period's financial results.
Nurix Therapeutics Quarterly report: Q3 2026
Nurix Therapeutics has published its Q3 2026 quarterly earnings report on October 13, 2026.
Nurix Therapeutics price target raised to $41 from $40 at Stifel
Stifel raised the firm’s price target on Nurix Therapeutics (NRIX) to $41 from $40 and keeps a Buy rating on the shares. The firm believes the Roche (RHHBY) collaboration “fundamentally…
Nurix Therapeutics reports Q3 EPS $4.73, consensus $5.11
Reports Q3 revenue $673.06M, consensus $479.52M. The revenue increase was primarily due to $653.2M of license revenue from the collaboration with Roche and $10M from the achievement of a development…
Nurix Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate Update
Dosed first patient in registrational Phase 3 DAYBreak CLL-306 trial comparing bexobrutideg with pirtobrutinib in relapsed/refractory CLL/SLL
Nurix Therapeutics Announces First Patient Enrolled in Phase 1b/2 Combination Study of Bexobrutideg in Chronic Lymphocytic Leukemia
First patient enrolled in cohort combining bexobrutideg with venetoclax Initial cohort to focus on relapsed/refractory CLL, with potential expansion to first-line CLL Strategy includes evaluation of b...
Nurix Therapeutics announces second research term extension with Gilead
Nurix Therapeutics (NRIX) announced that Nurix and Gilead (GILD) have agreed to extend the research term for an undisclosed oncology program within the companies’ ongoing strategic collaboration by an...
Nurix Therapeutics Announces Second Research Term Extension for Oncology Program Under Collaboration with Gilead Sciences
Two-year extension builds on productive relationship established in 2019 Nurix continues to retain co-development and 50/50 profit sharing options on up to two programs in the United States BRISBANE, ...
Nurix Therapeutics announces achievement of $7M milestone with Pfizer
Nurix Therapeutics (NRIX) announced the achievement of a $7M research milestone under its strategic collaboration with Pfizer (PFE) for the discovery and development of degrader antibody conjugates. N...
Nurix Therapeutics Announces Achievement of $7 Million Milestone Under Strategic Collaboration with Pfizer
BRISBANE, Calif., Sept. 29, 2026 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of ...
Nurix Therapeutics Transcript: Morgan Stanley 24th Annual Global Healthcare Conference
A landmark Roche partnership accelerates clinical and commercial plans for bexobrutideg in oncology and immunology, with major trials underway in CLL, NHL, CSU, and MS. Additional partnered programs with Sanofi and Gilead advance in STAT6 and IRAK4, supporting a robust, milestone-rich pipeline.
Nurix Therapeutics Transcript: H.C. Wainwright 28th Annual Global Investment Conference
A landmark Roche partnership expands the clinical and commercial reach of a BTK degrader, with pivotal trials underway and a strong safety profile supporting broad development in oncology and autoimmune diseases. Additional partnered programs and novel DAC technology further enhance future growth prospects.
Nurix Therapeutics Transcript: Wells Fargo 21st Annual Healthcare Conference
The discussion highlighted robust clinical progress for the BTK degrader in CLL, CSU, and MS, a landmark $700M+ partnership with Roche, and a diversified pipeline with multiple collaborations. Key updates are expected in pivotal CLL trials, CSU/MS phase I data, and new preclinical assets.
Nurix Therapeutics to Participate in Upcoming September Investor Conferences
BRISBANE, Calif., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of ...
Nurix Therapeutics Announces Appointment of Wes Burwell as Chief Human Resources Officer
BRISBANE, Calif., Aug. 20, 2026 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company developing targeted protein degradation medicines for patients w...
Nurix earns $10M milestone from Sanofi on STAT6 degrader Phase 1 start
Nurix Therapeutics (NRIX) announced that it has earned a $10M milestone payment following the initiation by its collaborator, Sanofi, of the Phase 1 first-in-human clinical trial of SAR448272/NX-3911,...
Nurix Announces $10 Million Milestone Payment Associated with Initiation of a Phase 1 Clinical Trial of a STAT6 Degrader
Oral STAT6 degrader advances into clinical development for type 2 inflammatory diseases Nurix has earned approximately $139 million to date under its collaboration with Sanofi and remains eligible to ...